TNFR1 Signaling and IFN-γ Signaling Determine whether T Cells Induce Tumor Dormancy or Promote Multistage Carcinogenesis

Cancer Cell

Volumn 13, Issue 6, 2008, Pages 507-518

  Müller Hermelink, Nele ^a   Braumüller, Heidi ^a   Pichler, Bernd ^b   Wieder, Thomas ^a   Mailhammer, Reinhard ^c   Schaak, Katrin ^a   Ghoreschi, Kamran ^a   Yazdi, Amir ^a   Haubner, Roland ^d,e   Sander, Christian A ^f   Mocikat, Ralph ^c   Schwaiger, Markus ^d   Förster, Irmgard ^g   Huss, Ralph ^h   Weber, Wolfgang A ^d   Kneilling, Manfred ^a   Röcken, Martin ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Department of Radiology Preclinical Imaging and Radiopharmacy Laboratory for Preclinical Imaging and Imaging Technology Werner Siemens Foundation   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f DEPARTMENT OF CARDIOLOGY   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

Author keywords

CELLCYCLE

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR RECEPTOR 1; VITRONECTIN RECEPTOR;

ADAPTIVE IMMUNITY; ADOLESCENT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL DESTRUCTION; CELL PROLIFERATION; DYSPLASIA; IMMUNE RESPONSE; MOUSE; NONHUMAN; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL TIME; T LYMPHOCYTE; TH1 CELL; TUMOR GROWTH;

EID: 44449137591     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.04.001     Document Type: Article

References (76)

1. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793
2. Agrawal S., Agarwal M.L., Chatterjee-Kishore M., Stark G.R., and Chisolm G.M. Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol-induced apoptosis. Mol. Cell. Biol. 22 (2002) 1981-1992
3. Arnott C.H., Scott K.A., Moore R.J., Robinson S.C., Thompson R.G., and Balkwill F.R. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23 (2004) 1902-1910
4. Baluk P., Morikawa S., Haskell A., Mancuso M., and McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163 (2003) 1801-1815
5. Bergers G., Javaherian K., Lo K.M., Folkman J., and Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
6. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., and Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000) 737-744
7. Berner V., Liu H., Zhou Q., Alderson K.L., Sun K., Weiss J.M., Back T.C., Longo D.L., Blazar B.R., Wiltrout R.H., et al. IFN-gamma mediates CD4(+) T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13 (2007) 354-360
8. Bhowmick N.A., Neilson E.G., and Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 432 (2004) 332-337
9. Biedermann T., Zimmermann S., Himmelrich H., Gumy A., Egeter O., Sakrauski A.K., Seegmuller I., Voigt H., Launois P., Levine A.D., et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2 (2001) 1054-1060
10. Billiau A. Interferon-gamma: Biology and role in pathogenesis. Adv. Immunol. 62 (1996) 61-130
11. Bissell M.J., and Radisky D. Putting tumours in context. Nat. Rev. Cancer 1 (2001) 46-54
12. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15 (1997) 749-795
13. Boon T., Coulie P.G., Van den Eynde B.J., and van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24 (2006) 175-208
14. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
15. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72 (1975) 3666-3670
16. Casanovas O., Hager J.H., Chun M.G., and Hanahan D. Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene 24 (2005) 6597-6604
17. Casanovas O., Hicklin D.J., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
18. Chamoto K., Wakita D., Narita Y., Zhang Y., Noguchi D., Ohnishi H., Iguchi T., Sakai T., Ikeda H., and Nishimura T. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res. 66 (2006) 1809-1817
19. Daniel D., Meyer-Morse N., Bergsland E.K., Dehne K., Coussens L.M., and Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J. Exp. Med. 197 (2003) 1017-1028
20. Daniel D., Chiu C., Giraudo E., Inoue M., Mizzen L.A., Chu N.R., and Hanahan D. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 65 (2005) 2018-2025
21. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6 (2006) 24-37
22. Egeter O., Mocikat R., Ghoreschi K., Dieckmann A., and Rocken M. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res. 60 (2000) 1515-1520
23. Folkman J., Watson K., Ingber D., and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 (1989) 58-61
24. Forster I., Hirose R., Arbeit J.M., Clausen B.E., and Hanahan D. Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen. Immunity 2 (1995) 573-585
25. Ganss R., Ryschich E., Klar E., Arnold B., and Hammerling G.J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62 (2002) 1462-1470
26. Garbi N., Arnold B., Gordon S., Hammerling G.J., and Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172 (2004) 5861-5869
27. Garcia-Lora A., Algarra I., and Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 195 (2003) 346-355
28. Greenberg P.D. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49 (1991) 281-355
29. Haagsma E.B., Hagens V.E., Schaapveld M., van den Berg A.P., de Vries E.G., Klompmaker I.J., Slooff M.J., and Jansen P.L. Increased cancer risk after liver transplantation: A population-based study. J. Hepatol. 34 (2001) 84-91
30. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
31. Haubner R., Wester H.J., Weber W.A., Mang C., Ziegler S.I., Goodman S.L., Senekowitsch-Schmidtke R., Kessler H., and Schwaiger M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61 (2001) 1781-1785
32. Holmgren L., Ambrosino E., Birot O., Tullus C., Veitonmaki N., Levchenko T., Carlson L.M., Musiani P., Iezzi M., Curcio C., et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc. Natl. Acad. Sci. USA 103 (2006) 9208-9213
33. Indraccolo S., Pfeffer U., Minuzzo S., Esposito G., Roni V., Mandruzzato S., Ferrari N., Anfosso L., Dell'Eva R., Noonan D.M., et al. Identification of genes selectively regulated by IFNs in endothelial cells. J. Immunol. 178 (2007) 1122-1135
34. Inoue M., Hager J.H., Ferrara N., Gerber H.P., and Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1 (2002) 193-202
35. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., and Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95 (1998) 7556-7561
36. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., and Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007) 903-907
37. Lin E.Y., Nguyen A.V., Russell R.G., and Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193 (2001) 727-740
38. Lin W.W., and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117 (2007) 1175-1183
39. MacKie R.M., Reid R., and Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 348 (2003) 567-568
40. Mocikat R., Braumuller H., Gumy A., Egeter O., Ziegler H., Reusch U., Bubeck A., Louis J., Mailhammer R., Riethmuller G., et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19 (2003) 561-569
41. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., Holdsworth H., Turner L., Rollins B., Pasparakis M., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 5 (1999) 828-831
42. Mumberg D., Monach P.A., Wanderling S., Philip M., Toledano A.Y., Schreiber R.D., and Schreiber H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA 96 (1999) 8633-8638
43. Nanni P., Nicoletti G., De Giovanni C., Landuzzi L., Di Carlo E., Cavallo F., Pupa S.M., Rossi I., Colombo M.P., Ricci C., et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194 (2001) 1195-1205
44. Nelson D.J., Mukherjee S., Bundell C., Fisher S., van Hagen D., and Robinson B. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J. Immunol. 166 (2001) 5557-5566
45. Nishikawa H., Kato T., Tawara I., Ikeda H., Kuribayashi K., Allen P.M., Schreiber R.D., Old L.J., and Shiku H. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J. Immunol. 175 (2005) 4433-4440
46. Nozawa H., Chiu C., and Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. USA 103 (2006) 12493-12498
47. Olieman A.F., Lienard D., Eggermont A.M., Kroon B.B., Lejeune F.J., Hoekstra H.J., and Koops H.S. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: A multicenter study. Arch. Surg. 134 (1999) 303-307
48. Otahal P., Schell T.D., Hutchinson S.C., Knowles B.B., and Tevethia S.S. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J. Immunol. 177 (2006) 3089-3099
49. Pannellini T., Spadaro M., Di Carlo E., Ambrosino E., Iezzi M., Amici A., Lollini P.L., Forni G., Cavallo F., and Musiani P. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J. Immunol. 176 (2006) 7695-7703
50. Pfaff M., Tangemann K., Muller B., Gurrath M., Muller G., Kessler H., Timpl R., and Engel J. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem. 269 (1994) 20233-20238
51. Pfeffer K., Matsuyama T., Kundig T.M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P.S., Kronke M., and Mak T.W. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73 (1993) 457-467
52. Prehn R.T. The immune reaction as a stimulator of tumor growth. Science 176 (1972) 170-171
53. Qin Z., and Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12 (2000) 677-686
54. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., Shevach E.M., and Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180 (1994) 1961-1966
55. Ramana C.V., Grammatikakis N., Chernov M., Nguyen H., Goh K.C., Williams B.R., and Stark G.R. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J. 19 (2000) 263-272
56. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10 (2004) 909-915
57. Ruegg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., and Lejeune F.J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med. 4 (1998) 408-414
58. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102 (2005) 18538-18543
59. Schadendorf D., Ugurel S., Schuler-Thurner B., Nestle F.O., Enk A., Brocker E.B., Grabbe S., Rittgen W., Edler L., Sucker A., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17 (2006) 563-570
60. Schultz E.S., Schuler-Thurner B., Stroobant V., Jenne L., Berger T.G., Thielemanns K., van der Bruggen P., and Schuler G. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J. Immunol. 172 (2004) 1304-1310
61. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., and Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
62. Siegel C.T., Schreiber K., Meredith S.C., Beck-Engeser G.B., Lancki D.W., Lazarski C.A., Fu Y.X., Rowley D.A., and Schreiber H. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J. Exp. Med. 191 (2000) 1945-1956
63. Soucek L., Lawlor E.R., Soto D., Shchors K., Swigart L.B., and Evan G.I. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13 (2007) 1211-1218
64. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., Hanahan D., Zinkernagel R.M., and Ohashi P.S. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J. Exp. Med. 186 (1997) 645-653
65. Spiotto M.T., Rowley D.A., and Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10 (2004) 294-298
66. Stewart T., Tsai S.C., Grayson H., Henderson R., and Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346 (1995) 796-798
67. Stoelcker B., Ruhland B., Hehlgans T., Bluethmann H., Luther T., and Mannel D.N. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am. J. Pathol. 156 (2000) 1171-1176
68. Street S.E., Trapani J.A., MacGregor D., and Smyth M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 196 (2002) 129-134
69. Suganuma M., Okabe S., Marino M.W., Sakai A., Sueoka E., and Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 59 (1999) 4516-4518
70. Suganuma M., Kuzuhara T., Yamaguchi K., and Fujiki H. Carcinogenic role of tumor necrosis factor-alpha inducing protein of Helicobacter pylori in human stomach. J. Biochem. Mol. Biol. 39 (2006) 1-8
71. Tannenbaum C.S., Tubbs R., Armstrong D., Finke J.H., Bukowski R.M., and Hamilton T.A. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161 (1998) 927-932
72. Valmori D., Dutoit V., Rubio-Godoy V., Chambaz C., Lienard D., Guillaume P., Romero P., Cerottini J.C., and Rimoldi D. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res. 61 (2001) 509-512
73. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
74. Yao V.J., Ozawa M.G., Varner A.S., Kasman I.M., Chanthery Y.H., Pasqualini R., Arap W., and McDonald D.M. Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res. 66 (2006) 2639-2649
75. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., and Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99 (2002) 16168-16173
76. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J. Exp. Med. 195 (2002) F9-F14